This is a working overview of tissue repair, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-29. Anything still debated is marked as such rather than presented as settled.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
== Research == Burnham's research is focused on rapid pathogen identification and antibiotic susceptibility testing to prevent infectious diseases. Burnham edited the Journal of Clinical Microbiology, the Clinical Microbiology Newsletter, Clinics in Laboratory Medicine, and the Manual of Clinical Microbiology. She is the co-editor of the textbook The Dark Art of Blood Cultures, which received praise in the Journal of Clinical Microbiology, where Stephen M. Brecher called the work, "a wonderful historical perspective of the past, present, and future of blood cultures." She has had her work on the topic of diagnostic and clinical microbiology published over two hundred times.
== Origins == Extensive pan-Slavism emerged much like Pan-Germanism; both movements flourished from the sense of unity and nationalism experienced by members of many European ethnic groups in the aftermath of the French Revolution and the consequent Napoleonic Wars, as a pushback against traditional European monarchies. As in other Romantic nationalist movements, Slavic intellectuals and scholars in the developing fields of history, philology, and folklore actively encouraged Slavs' interest in their shared identity and ancestry. Pan-Slavism co-existed with the Southern Slavic drive towards independence. Commonly used symbols of the Pan-Slavic movement were the Pan-Slavic colours (blue, white, and red) and the Pan-Slavic anthem, Hey, Slavs. The first pan-Slavists were the 16th-century Croatian writer Vinko Pribojević, the Dalmatian Aleksandar Komulović (1548–1608), the Croat Bartol Kašić (1575–1650), the Ragusan Ivan Gundulić (1589–1638), and the Croatian Catholic missionary Juraj Križanić (c. 1618 – 1683). Additionally, scholars such as Tomasz Kamusella have attributed early manifestations of Pan-Slavic thought within the Habsburg monarchy to the Slovaks Adam Franz Kollár (1718–1783) and Pavel Jozef Šafárik (1795–1861). The Pan-Slavism movement grew rapidly following the end of the Napoleonic Wars in 1815. In the aftermath of the wars, the leaders of Europe sought to restore the pre-war status quo.
Open science norms now encourage researchers to deposit raw reads and alignments in public repositories and cite them in taxonomic papers. These practices enhance reproducibility and let future studies reuse data instead of repeating the work. Even with abundant data, key limitations remain. Lücking (2020) notes that larger datasets do not guarantee better science; sound design, critical analysis, and accurate taxonomy remain essential. A poorly designed study can mislead whether it uses five genes or 5,000 with the error merely scaling up. The aim, then, is to deploy new tools to answer deeper questions, not simply to stockpile sequences. Practitioners advocate a 'minimum adequate method': if five markers plus morphology solve a species boundary, a whole genome is unnecessary. Conversely, issues such as dating deep divergences or detecting genome-wide hybridization do require phylogenomic data. The next-generation sequencing era has accelerated discovery and opened new questions, but it builds on the framework laid by morphology and Sanger sequencing.
Banting lived at the house in London for ten months, beginning in June, 1920. He attempted a private medical practice and when it was unsuccessful, he began working at the University of Western Ontario; his research for a lecture there was what inspired his 25 word idea that provided the key to discovering insulin, and prevented the certain death of those affected by diabetes. Banting returned to the University of Toronto to begin his research on insulin in the spring of 1921. Banting House is dedicated to the story behind the discovery of insulin, as well as Banting's life and career. Its galleries focus on everything from his time spent in London, to his contributions in both World Wars, to his efforts as an artist. Some notable artifacts include Banting's original art, desk, medicine cabinet, and bed frame, as well as his Military Cross, the KBE, and his official replica of the Nobel Prize. Banting House was designated a National Historic Site of Canada in 1997.
Gas phase ion chemistry is a field of science encompassed within both chemistry and physics. It is the science that studies ions and molecules in the gas phase, most often enabled by some form of mass spectrometry. By far the most important applications for this science is in studying the thermodynamics and kinetics of reactions. For example, one application is in studying the thermodynamics of the solvation of ions. Ions with small solvation spheres of 1, 2, 3... solvent molecules can be studied in the gas phase and then extrapolated to bulk solution. Transition state theory is the theory of the rates of elementary reactions which assumes a special type of chemical equilibrium (quasi-equilibrium) between reactants and activated complexes. RRKM theory is used to compute simple estimates of the unimolecular ion decomposition reaction rates from a few characteristics of the potential energy surface.
Sources: en.wikipedia.org
12(S)-HETE and 12(S)-HpETE stimulate the dilation of rat mesenteric arteries; 12(S)-HETE stimulates the dilation of coronary microvessels in pigs and the mesenteric arteries of mice, one or more of these three metabolites are implicated in the vasodilation of rat basilar artery, 12(R)-HETE and to a slightly lesser extent 12(S)-HETE constrict the renal artery of dogs and 12-HETE (stereoisomer undetermined) is implicated in the angiotensin II-induced arterial hypertension response of human placenta. The vasodilating effect on mouse mesenteric arteries appears due to 12S-HETE's ability to act as a thromboxane receptor antagonist and thereby block the vasoconstricting actions of thromboxane A2. These results indicate that the cited metabolites have dilating or constricting effects that depend on the arterial vascular site and or species of animal examined; their role in human blood pressure regulation is unclear. Excessive 12-HETE production is implicated in psoriasis. 5-Hydroxyeicosatetraenoic acid 15-Hydroxyeicosatetraenoic acid
Irradiation of 241Am by 12C or 22Ne ions yields the isotopes 247Es (einsteinium) or 260Db (dubnium), respectively. Furthermore, the element berkelium (243Bk isotope) had been first intentionally produced and identified by bombarding 241Am with alpha particles, in 1949, by the same Berkeley group, using the same 60-inch cyclotron. Similarly, nobelium was produced at the Joint Institute for Nuclear Research, Dubna, Russia, in 1965 in several reactions, one of which included irradiation of 243Am with 15N ions. Besides, one of the synthesis reactions for lawrencium, discovered by scientists at Berkeley and Dubna, included bombardment of 243Am with 18O.
=== Controversy and response === Following the reports in 2007 that Avandia can significantly increase the risk of heart attacks, the drug has been controversial. A 2010 article in Time uses the Avandia case as evidence of a broken FDA regulatory system that "may prove criminal as well as fatal". It details the disclosure failures, adding, "Congressional reports revealed that GSK sat on early evidence of the heart risks of its drug, and that the FDA knew of the dangers months before it informed the public." It reports, "the FDA is investigating whether GSK broke the law by failing to fully inform the agency of Avandia's heart risks", according to deputy FDA commissioner Dr. Joshua Sharfstein. GSK threatened academics who reported adverse research results, and received multiple warning letters from the FDA for deceptive marketing and failure to report clinical data. The maker of the drug, GlaxoSmithKline, has dealt with serious backlash against the company for the drug's controversy. Sales on the drug dropped significantly after the story first broke in 2007, dropping from $2.5 billion in 2006 to less than $408 million in 2009 in the US. In response to the rise in risk of heart attacks, the Indian government ordered GSK to suspend its research study, called TIDE, in 2010. The FDA also halted the TIDE study in the United States.
=== Isoprene === Isoprene is a natural monomer that polymerizes to form a natural rubber, most often cis-1,4-polyisoprene, but also trans-1,4-polymer. Synthetic rubbers are often based on butadiene, which is structurally related to isoprene.
In the field of pharmacokinetics, the area under the curve (AUC) is the definite integral of the concentration of a drug in blood plasma as a function of time (this can be done using liquid chromatography–mass spectrometry). In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage (called "area under the curve" or AUC) gives insight into the extent of exposure to a drug and its clearance rate from the body.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.